Lucy Pemberton

411 total citations
7 papers, 97 citations indexed

About

Lucy Pemberton is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Lucy Pemberton has authored 7 papers receiving a total of 97 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hematology, 3 papers in Genetics and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Lucy Pemberton's work include Chronic Myeloid Leukemia Treatments (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Lymphoma Diagnosis and Treatment (2 papers). Lucy Pemberton is often cited by papers focused on Chronic Myeloid Leukemia Treatments (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Lymphoma Diagnosis and Treatment (2 papers). Lucy Pemberton collaborates with scholars based in United Kingdom, United States and Australia. Lucy Pemberton's co-authors include Shannon K. McWeeney, Brian Druker, Michael W. Deininger, Junia V. Melo, Raji Pillai, Beth Wilmot, Kristina Vartanian, Yaron Turpaz, Mary MacPartlin and Thoralf Lange and has published in prestigious journals such as Blood, Kew Bulletin and Journal of Adolescent and Young Adult Oncology.

In The Last Decade

Lucy Pemberton

6 papers receiving 95 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lucy Pemberton United Kingdom	3	83	70	34	13	12	7	97
Craig A. Kovitz United States	4	87 1.0×	74 1.1×	44 1.3×	7 0.5×	20 1.7×	13	131
G Rosti Italy	6	107 1.3×	89 1.3×	47 1.4×	24 1.8×	7 0.6×	10	131
Astghik Voskanyan Germany	3	62 0.7×	48 0.7×	17 0.5×	19 1.5×	9 0.8×	9	71
A. Guerci-Bresler United States	4	161 1.9×	145 2.1×	24 0.7×	8 0.6×	14 1.2×	8	171
Benoît De Renzis France	5	117 1.4×	89 1.3×	29 0.9×	14 1.1×	67 5.6×	15	138
Jolanta Dengler Germany	6	165 2.0×	140 2.0×	83 2.4×	20 1.5×	6 0.5×	16	170
Paul Kotzampaltiris United Kingdom	2	87 1.0×	74 1.1×	56 1.6×	7 0.5×	4 0.3×	2	92
Laure Morisset France	4	70 0.8×	39 0.6×	22 0.6×	16 1.2×	42 3.5×	5	119
Elza Lomaia Russia	7	138 1.7×	129 1.8×	69 2.0×	15 1.2×	27 2.3×	34	153
Aimee Jackson United Kingdom	5	41 0.5×	31 0.4×	8 0.2×	11 0.8×	22 1.8×	14	85

Countries citing papers authored by Lucy Pemberton

Since Specialization

Citations

This map shows the geographic impact of Lucy Pemberton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucy Pemberton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucy Pemberton more than expected).

Fields of papers citing papers by Lucy Pemberton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucy Pemberton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucy Pemberton. The network helps show where Lucy Pemberton may publish in the future.

Co-authorship network of co-authors of Lucy Pemberton

This figure shows the co-authorship network connecting the top 25 collaborators of Lucy Pemberton. A scholar is included among the top collaborators of Lucy Pemberton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucy Pemberton. Lucy Pemberton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Pemberton, Lucy, Katrina Sharples, Yujin Kim, et al.. (2023). P675: IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY. HemaSphere. 7(S3). e4174924–e4174924. 1 indexed citations

2.

Ballantine, Kirsten, et al.. (2019). An Age Stratified Analysis of the Access to Care Continuum Across Three Tumor Groups: Are There Delays for AYA?. Journal of Adolescent and Young Adult Oncology. 8(4). 402–409. 3 indexed citations

3.

McWeeney, Shannon K., Gregory S. Yochum, Lucy Pemberton, et al.. (2009). A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.. Blood. 114(22). 508–508. 1 indexed citations

4.

McWeeney, Shannon K., Lucy Pemberton, Marc Loriaux, et al.. (2009). A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 115(2). 315–325. 86 indexed citations

5.

McWeeney, Shannon K., et al.. (2007). A Transcriptomal Profile for Predicting Complete Cytogenetic Response (CCR) in Chronic Phase CML Patients Treated with Imatinib.. Blood. 110(11). 1007–1007. 2 indexed citations

6.

Pemberton, Lucy. (1999). Guillain-Barré syndrome.. PubMed. 94(46). 50–3. 3 indexed citations

7.

Pemberton, Lucy & Jules Janick. (1973). Horticultural Science. Second Edition. Kew Bulletin. 28(2). 331–331. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact